In 2014, the Food & Drug Administration (FDA) issued draft guidance focused on advertising for pharmaceuticals and medical devices on space constrained platforms. In addition to filing comments, in March of 2015, IAB led an industry group to the FDA, where we had a nearly three hour dialog on the issue. During the meeting we asked the FDA to consider allowing character-space-limited communications to include benefit information (including indication) for a prescription drug or device as long as risk information was accessible within a reasonable click route from the initial communication.
In the intervening years, we continued to push the FDA on the issue when possible. We pursued related amendments in Congress and sent letters to continue to drive the issue forward. We also published an op-ed on the issue, which was featured in AdWeek last week.
On Monday, the FDA filed a notice in the federal register indicating their intent to conduct a test that essentially mirrors our ask. We are currently preparing a response as part of our ongoing effort to drive this forward.
